News Releases & Research Results Discovery of a causative protein for thalidomide teratogenicity - Mechanism of the adverse effects of thalidomide -
News Releases & Research Results
The results of research conducted by Research Fellow Satoshi Yamanaka and Professor Tatsuya Sawasaki of the Proteo-Science Center, Ehime University, Professor Koji Tamura of the Graduate School of Life Sciences, Tohoku University, Associate Professor Takayuki Suzuki of the Graduate School of Bioagricultural Sciences, Nagoya University, and Professor Norio Shibata of the Graduate School of Engineering, Nagoya Institute of Technology.
The key results of research are as follows:
- PLZF (Promyelocytic Leukemia Zinc Finger) was identified as the novel protein responsible for thalidomide teratogenicity, leading to the elucidation of the molecular mechanism of thalidomide teratogenicity.
- The results of this research project should greatly facilitate the development of new thalidomide derivatives with the reduction of adverse effects, which are being actively investigated all over the world.
This project was conducted with the support of the Platform Project for Supporting Drug Discovery and Life Science Research (BINDS) by AMED.
The results were published in THE EMBO JOURNAL on January 20.
Yamanaka S., et al. Thalidomide and its metabolite 5-hydroxythalidomide induce teratogenicity via the cereblon neosubstrate PLZF THE EMBO JOURNAL
Last updated 2021.1.20